Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

YD Bio Limited (YDES) Stock Price & Analysis

YDES Stock Chart & Stats

$5.94$0.07(1.19%)
At close: 4:00 PM EDT
$2.5$5$7.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$5.67 - $6.10
52-Week Range
$1.70 - $15.72
Previous Close
$5.87
Volume
N/A
Average Volume (3M)
331.70K
Market Cap
$420.81M
Enterprise Value
$156.71M
Total Cash (Recent Filing)
$6,312
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.28
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Equity Position

The return to positive shareholders’ equity materially improves the company’s financial standing compared with year-end 2025. Although the change largely reflected lower warrant liabilities, it may reduce immediate balance-sheet pressure and improve flexibility with creditors and future funding.

Strong Revenue Growth

Revenue growth of this magnitude indicates expanding commercial activity and provides evidence that the company is generating greater demand than in the prior-year period. If sustained, the larger revenue base could support operating leverage and strengthen the foundation for future healthcare commercialization.

Physician-Led Product Expansion

The Taiwan launch broadens YD Bio beyond development toward commercial healthcare products and uses clinician partnerships to support product credibility and distribution. A repeatable, capital-light model could create recurring consumer-health revenue while connecting nutraceuticals with diagnostics and clinical services.

Bears Say

Persistent Cash Burn

Persistent negative operating and free cash flow show that the business is not yet self-funding its operations. Accelerating burn increases dependence on external capital, limits financial flexibility, and could pressure the company to raise funds on unfavorable terms if liquidity needs remain elevated.

Weak Profitability

The shift from modest profitability in 2023 to significant losses in 2024–2025 indicates that growth has not yet translated into a sustainable earnings model. Negative gross profit and weak operating leverage make future profitability dependent on stronger revenue scale or substantial cost improvement.

High Operating Cost Relative To Revenue

Operating expenses substantially exceeded reported revenue in the latest period, showing that the current commercial base is too small to support the cost structure. Unless revenue expands faster than expenses, continued operating losses could offset the benefits of product launches and equity improvement.

YD Bio Limited News

YDES FAQ

What was YD Bio Limited’s price range in the past 12 months?
YD Bio Limited lowest stock price was $1.70 and its highest was $15.72 in the past 12 months.
What is YD Bio Limited’s market cap?
YD Bio Limited’s market cap is $420.81M.
When is YD Bio Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were YD Bio Limited’s earnings last quarter?
YD Bio Limited released its earnings results on Aug 31, 2026. The company reported $0.095 earnings per share for the quarter.
Is YD Bio Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does YD Bio Limited pay dividends?
YD Bio Limited does not currently pay dividends.
What is YD Bio Limited’s EPS estimate?
YD Bio Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does YD Bio Limited have?
YD Bio Limited has 70,842,840 shares outstanding.
What happened to YD Bio Limited’s price movement after its last earnings report?
YD Bio Limited reported an EPS of $0.095 in its last earnings report. Following the earnings report the stock price went up 1.752%.
Which hedge fund is a major shareholder of YD Bio Limited?
Currently, no hedge funds are holding shares in YDES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology